ArticleJACC. Advances2026
Article in JACC. Advances, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Diagnostic Sensitivity of [18F]-Florbetaben-PET/CT in Detecting Cardiac Involvement in AL Amyloidosis: The Prospective MoRBiDA Study.JACC. Advances · 2026Article
- Diagnostic value of positron emission tomography using amyloid-binding radiotracers for cardiac amyloidosis: a systematic review and meta-analysis.European heart journal. Imaging methods and practice · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
22 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
background
objectivesThe purpose of this study was to identify CA and differentiate AL-CA from ATTR-CA (transthyretin) by evaluating cardiac and multi-organ involvement with whole-body
methodsMulticentric study of 61 patients with left ventricular hypertrophy due to AL-CA (n = 25), ATTR-CA (n = 25), and aortic stenosis (n = 11, controls). A 20-minute whole-body PET was preceded by a 10-minute dynamic cardiac PET recording started during
resultsTracer uptake was significantly increased in whole-body PET of CA patients compared to controls, with AL-CA patients, in particular, exhibiting increased uptake in myocardium, lung, and spleen, and decreased uptake in blood, salivary glands, skeletal muscle, and liver. Among cardiac parameters, the myocardial/blood standardized uptake value (SUV)max ratio from whole-body PET best differentiated AL-CA from ATTR-CA, with 90% (55/61) of patients identified correctly (kappa value: 0.819) using SUVmax ratio thresholds of 2-to-4 for ATTR-CA and >4 for AL-CA. When combining cardiac with extracardiac PET variables, the selected multivariate predictors were myocardial uptake volume and the lung and salivary gland SUVmean. Thresholds of myocardial uptake volume >10 mL for CA and lung/salivary gland SUVmean >0.285 for AL-CA correctly identified 93% (57/61) of patients (kappa value: 0.871). PET variables improved the overall prediction provided by the bone scan Perugini score (P < 0.001).
conclusionsWhole-body
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.